



Expert UK-based CRO offering customised bioassay development, pharmacological profiling and compound screening

Welcome to the latest edition of our newsletter

Read our latest newsletter to find out what's happening at Aurelia Bioscience!

International Women's Day video

As we celebrated International Women's Day across the world last month, here's a short video featuring Aurelia Bioscience's Science Director, Kathy Dodgson: <http://bit.ly/2PsWCgy>

Not only is Kathy a remarkable scientist, but also one of the very few female directors to be on the board of a life science SME. She has over 20 years of industrial experience gained at Smith-Kline-Beecham and AstraZeneca and has worked on the development and implementation of new screening approaches including FMAT and recently label-free screening. As the co-founder and science director of Aurelia Bioscience, Kathy successfully splits her time between managing staff and leading client projects.




New article on Kinase profiling

The role of kinases in human disease is well known in the drug discovery world, making them significant therapeutic intervention points. There are over 500 known kinases in the human kinome and over 150 are mutated or misregulated in various disease states. However, developing a selective kinase inhibitor can be both challenging and time consuming. There is thus an increasing demand for broad kinase compound profiling services. This article summarises some proven techniques used for kinase profiling. *Follow the link to read the full article:* <http://bit.ly/2PtG1sR>

NanoBRET™ bags the Scientists' Choice award!

We are pleased to share that Select Science reviewers have chosen Promega's NanoBRET™ Target Engagement Intracellular Kinase Assays as "Drug Discovery & Development Product of the Year for 2019".


Using NanoBRET™ technology, our scientists have implemented intracellular kinase assays designed to study the interaction of compounds on kinase targets in intact living cells. *Follow the link to learn more:* <http://bit.ly/2PyUns8>



Drug Discovery Chemistry: San Diego, USA

Our Chief Scientific Officer, Gary Allenby and Marketing Manager, Payash Bahuguna represented Aurelia Bioscience at the 'CHI's 14th Annual Drug Discovery Chemistry conference' in San Diego, USA from 8th-12th April. We had a great response at our exhibition booth as well as our poster on 'Prosecution of the CDK Family Using NanoBRET Intracellular Engagement to Examine Clinically Relevant Inhibitors for Target Engagement and Residency Time Measurements in Living Cells'.

Contact us for a copy of the poster: info@areliabio.com



Upcoming events

Catch us at the following events this quarter:

- 2nd RSC Anglo-Nordic Medicinal Chemistry symposium: Snekersten, Denmark • June 11-14
- World Preclinical Congress: Boston, USA • June 17-20

Contact Information:

Aurelia Bioscience
BioCity Nottingham,
Pennyfoot Street,
Nottingham NG1 1GF
United Kingdom

Phone: +44 (0)115 837 0503

Email: info@areliabio.com

Web: www.aureliabio.com